Monday, 3 May 2021

NATCO receives Emergency Use approval for Baricitinib tablets for Covid-19 treatment

NATCO receives Emergency Use approval for Baricitinib tablets for Covid-19 treatment
NATCO receives Emergency Use approval for Baricitinib tablets for Covid-19 treatment

Natco Pharma Limited has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India. Baricitinib in combination with Remdesivir, is used for treatment of COVID-19 positive patients.

admin Mon, 05/03/2021 - 16:07

source https://www.pharmatutor.org/pharma-news/2021/natco-receives-emergency-use-approval-for-baricitinib-tablets-for-covid-19-treatment

No comments:

Post a Comment

Pharma openings

  Opportunity for M.Pharm, Msc or PhD as Scientist at PGIMER M.Pharmacy or M.Sc 6 Year of Research Experience or PhD with 3 year of Experien...